Coming together to overcome challenges
Creative Destruction Lab (CDL), a nonprofit organization that delivers an objectives-based program for massively scalable, seed-stage, science-and-technology-based companies, established the Rapid Screening Consortium to keep employees and customers safe as workplaces reopen. CDL's mission is to accelerate the commercialization of science for the betterment of humankind. And in August 2020, Genpact joined as a founding Consortium member to work alongside businesses including Air Canada, Scotiabank, and Shoppers Drug Mart.
The Consortium aims to roll out a large-scale COVID-19 screening program to administer cost-effective screening, produce results within 15 minutes, and deliver a false-negative infectiousness rate of less than 10%. It needed end-to-end process expertise to deliver the program and, more importantly, to capture and assess the data accurately to continually improve outcomes.
Our expertise was called upon to develop and deliver intelligent, data-driven cost frameworks and modeling capabilities so that the program could be rolled out across Canada.
The Consortium executed its work in four phases:
Phase one: Assessing the test landscape with a standardized approach
The Consortium's first step was to assess the potential of a complex and constantly evolving universe of tests – many of which had not yet been approved by regulators. Genpact examined the possible line-item costs of administering each test and built a single framework to standardize budgeting and cost reporting across all test use cases. This allowed us to accurately estimate costs across multiple screening site locations and screening protocols during the feasibility phase.
Phase two: A data-driven approach to determine feasibility
With the framework in place, the Consortium narrowed the universe of potential tests to those that were most feasible. We worked with the Canada Pension Plan Investment Board (CPPIB) to develop an intelligent cost-estimate and reporting model for the selected tests and their delivery scenarios.
With our analytics expertise and process-design experience, we integrated an exhaustive list of variables – including population, number of screens to be executed, labor costs, and testing protocols – into the cost model. Six iterations later, the refined model automated more than 140 screening cost estimates for member organizations and, armed with all the information they needed, the pilot phase began.
Phase three: Piloting the program
Screening pilots are well underway for members' employees. And we have given them the tools to capture and report budgeted versus actual cost data to paint an accurate picture of the cost impact of different screening scenarios. They range from screens administered by a medical or trained professional, guided in-person or remote self-testing, and a completely outsourced approach.
Phase four: Widespread implementation
The Consortium is in its final phase of scaling, and with more than 137,000 rapid tests administered across 137 pilot sites, numbers are growing each week. It's on its ninth cohort of pilot site preparation, with more than 75 member organizations. The cost model we built with the CPPIB continues to be used across pilot sites for budgeting and cost reporting to inform us of trends and best practices.
By learning as we go and sharing information, we're building accuracy and confidence in the system as we stride toward a screening process that costs less than $1 per test without sacrificing effectiveness.